These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35884895)

  • 1. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.
    Andón FT; Leon S; Ummarino A; Redin E; Allavena P; Serrano D; Anfray C; Calvo A
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
    Xun Y; Yang H; Kaminska B; You H
    J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment.
    Zheng R; Ma J
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
    Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
    Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
    Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
    Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial watch: Toll-like receptor ligands in cancer therapy.
    Le Naour J; Kroemer G
    Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer.
    Haegebaert RMS; Kempers M; Ceelen W; Lentacker I; Remaut K
    Eur J Pharm Biopharm; 2022 Mar; 172():16-30. PubMed ID: 35074555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
    Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.
    Veneziani I; Alicata C; Moretta L; Maggi E
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral delivery of TransCon
    Zúñiga LA; Leßmann T; Uppal K; Bisek N; Hong E; Rasmussen CE; Karlsson JJ; Zettler J; Holten-Andersen L; Bang K; Thakar D; Lee YC; Martinez S; Sabharwal SS; Stark S; Faltinger F; Kracker O; Weisbrod S; Müller R; Voigt T; Bigott K; Tabrizifard M; Breinholt VM; Mirza AM; Rosen DB; Sprogøe K; Punnonen J
    Cancer Cell Int; 2022 Sep; 22(1):286. PubMed ID: 36123697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.
    Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Langer R; Zugates GT; Anderson DG; Kornbluth RS
    PLoS One; 2009 Oct; 4(10):e7334. PubMed ID: 19812695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities.
    Haroun R; Naasri S; Oweida AJ
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-Like Receptor 9 Agonists in Cancer.
    Karapetyan L; Luke JJ; Davar D
    Onco Targets Ther; 2020; 13():10039-10060. PubMed ID: 33116588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.